Administration of a poly ADP-ribose polymerase (PARP) inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life (QoL) during treatment, according to a study presented at the European Society for Medical Oncology 2017 Congress (Madrid, Spain; September 8-12, 2017).
NEW YORK (Reuters Health) - Olaparib maintenance therapy extends progression-free survival in women with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation, according to results from the SOLO2/ENGOT-Ov21 trial.
NEW YORK (Reuters Health) - The U.S. Preventive Services Task Force (USPSTF) continues to advise against ovarian cancer screening in asymptomatic women at average risk, saying the potential harms of screening outweigh the benefits.
Though proven to offer superior outcomes versus other treatment regimens, less than half of patients receive standard of care for locally advanced cervical cancer, according to a study published in Gynecologic Oncology.
In a study published in JAMA Oncology, researchers a found that, after adjusting for changes in screening, there was a decrease in all-grade cervical intraepithelial neoplasia (CIN), a known link to cervical cancer, among women 15-19 years old who received the human papillomavirus (HPV) vaccine.
Primary cytoreductive surgery (PCS) may improve survival for patients with stage III ovarian cancer, while neoadjuvant chemotherapy may be the optimal treatment for patients with stage IV disease, reported researchers in the Journal of Clinical Oncology, who examined the use and effectiveness of neoadjuvant chemotherapy in clinical practice.
Administering immunotherapy immediately after chemotherapy may improve response when treating patients with stage IIIC-IV tubo-ovarian high-grade serous carcinoma, according to findings from a study published in Clinical Cancer Research.